ID   NTRK3_HUMAN             Reviewed;         839 AA.
AC   Q16288; B7Z4C5; E9PG56; H0YND1; O75682; Q12827; Q16289;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 2.
DT   12-OCT-2022, entry version 227.
DE   RecName: Full=NT-3 growth factor receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=GP145-TrkC;
DE            Short=Trk-C;
DE   AltName: Full=Neurotrophic tyrosine kinase receptor type 3;
DE   AltName: Full=TrkC tyrosine kinase;
DE   Flags: Precursor;
GN   Name=NTRK3; Synonyms=TRKC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Fetal brain;
RX   PubMed=7806211; DOI=10.1006/geno.1994.1383;
RA   McGregor L.M., Baylin S.B., Griffin C.A., Hawkins A.L., Nelkin B.D.;
RT   "Molecular cloning of the cDNA for human TrkC (NTRK3), chromosomal
RT   assignment, and evidence for a splice variant.";
RL   Genomics 22:267-272(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), AND PARTIAL PROTEIN
RP   SEQUENCE.
RC   TISSUE=Brain;
RX   PubMed=7823156; DOI=10.1523/jneurosci.15-01-00477.1995;
RA   Shelton D.L., Sutherland J., Gripp J., Camerato T., Armanini M.P.,
RA   Phillips H.S., Carroll K., Spencer S.D., Levinson A.D.;
RT   "Human trks: molecular cloning, tissue distribution, and expression of
RT   extracellular domain immunoadhesins.";
RL   J. Neurosci. 15:477-491(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9778053; DOI=10.1038/sj.onc.1202100;
RA   Ichaso N., Rodriguez R.E., Martin-Zanca D., Gonzalez-Sarmiento R.;
RT   "Genomic characterization of the human trkC gene.";
RL   Oncogene 17:1871-1875(1998).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   FUNCTION, PHOSPHORYLATION AT TYR-516, INVOLVEMENT IN CHD, VARIANTS PHE-21;
RP   VAL-71; MET-93; ILE-163; PHE-533 AND MET-817, CHARACTERIZATION OF VARIANTS
RP   MET-93; ILE-163; PHE-533 AND MET-817, AND MUTAGENESIS OF LYS-572.
RX   PubMed=25196463; DOI=10.1002/humu.22688;
RA   Werner P., Paluru P., Simpson A.M., Latney B., Iyer R., Brodeur G.M.,
RA   Goldmuntz E.;
RT   "Mutations in NTRK3 suggest a novel signaling pathway in human congenital
RT   heart disease.";
RL   Hum. Mutat. 35:1459-1468(2014).
RN   [7]
RP   INTERACTION WITH PTPRS.
RX   PubMed=25385546; DOI=10.1038/ncomms6209;
RA   Coles C.H., Mitakidis N., Zhang P., Elegheert J., Lu W., Stoker A.W.,
RA   Nakagawa T., Craig A.M., Jones E.Y., Aricescu A.R.;
RT   "Structural basis for extracellular cis and trans RPTPsigma signal
RT   competition in synaptogenesis.";
RL   Nat. Commun. 5:5209-5209(2014).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 297-401, AND DISULFIDE BOND.
RX   PubMed=10388563; DOI=10.1006/jmbi.1999.2816;
RA   Ultsch M.H., Wiesmann C., Simmons L.C., Henrich J., Yang M., Reilly D.,
RA   Bass S.H., de Vos A.M.;
RT   "Crystal structures of the neurotrophin-binding domain of TrkA, TrkB and
RT   TrkC.";
RL   J. Mol. Biol. 290:149-159(1999).
RN   [9]
RP   VARIANTS [LARGE SCALE ANALYSIS] ARG-149; CYS-306; LEU-307; GLN-336;
RP   TYR-677; GLN-678; ARG-768 AND LYS-781.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [10]
RP   VARIANTS SER-664; TYR-677; CYS-736; PRO-745 AND PHE-766.
RX   PubMed=18293376; DOI=10.1002/humu.20707;
RA   Marchetti A., Felicioni L., Pelosi G., Del Grammastro M., Fumagalli C.,
RA   Sciarrotta M., Malatesta S., Chella A., Barassi F., Mucilli F.,
RA   Camplese P., D'Antuono T., Sacco R., Buttitta F.;
RT   "Frequent mutations in the neurotrophic tyrosine receptor kinase gene
RT   family in large cell neuroendocrine carcinoma of the lung.";
RL   Hum. Mutat. 29:609-616(2008).
CC   -!- FUNCTION: Receptor tyrosine kinase involved in nervous system and
CC       probably heart development. Upon binding of its ligand
CC       NTF3/neurotrophin-3, NTRK3 autophosphorylates and activates different
CC       signaling pathways, including the phosphatidylinositol 3-kinase/AKT and
CC       the MAPK pathways, that control cell survival and differentiation.
CC       {ECO:0000269|PubMed:25196463}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028};
CC   -!- SUBUNIT: Exists in a dynamic equilibrium between monomeric (low
CC       affinity) and dimeric (high affinity) structures (By similarity). Binds
CC       SH2B2. Interacts with SQSTM1 and KIDINS220 (By similarity). Interacts
CC       with PTPRS (PubMed:25385546). Interacts with MAPK8IP3/JIP3 (By
CC       similarity). {ECO:0000250|UniProtKB:P04629,
CC       ECO:0000250|UniProtKB:Q03351, ECO:0000269|PubMed:25385546}.
CC   -!- INTERACTION:
CC       Q16288; Q16832: DDR2; NbExp=2; IntAct=EBI-3936704, EBI-1381484;
CC       Q16288; Q6PKX4: DOK6; NbExp=3; IntAct=EBI-3936704, EBI-2880244;
CC       Q16288; Q15375: EPHA7; NbExp=2; IntAct=EBI-3936704, EBI-1383428;
CC       Q16288; P08581: MET; NbExp=2; IntAct=EBI-3936704, EBI-1039152;
CC       Q16288; P04629: NTRK1; NbExp=2; IntAct=EBI-3936704, EBI-1028226;
CC       Q16288; Q16620: NTRK2; NbExp=3; IntAct=EBI-3936704, EBI-3904881;
CC       Q16288; P18031: PTPN1; NbExp=2; IntAct=EBI-3936704, EBI-968788;
CC       Q16288; P61619: SEC61A1; NbExp=2; IntAct=EBI-3936704, EBI-358919;
CC       Q16288; Q9UBV2: SEL1L; NbExp=2; IntAct=EBI-3936704, EBI-358766;
CC       Q16288; Q99523: SORT1; NbExp=2; IntAct=EBI-3936704, EBI-1057058;
CC   -!- SUBCELLULAR LOCATION: Membrane; Single-pass type I membrane protein.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=1; Synonyms=A;
CC         IsoId=Q16288-1; Sequence=Displayed;
CC       Name=2; Synonyms=B;
CC         IsoId=Q16288-2; Sequence=VSP_002925, VSP_002926;
CC       Name=3; Synonyms=C;
CC         IsoId=Q16288-3; Sequence=VSP_002927;
CC       Name=4; Synonyms=D;
CC         IsoId=Q16288-4; Sequence=VSP_002924;
CC       Name=5; Synonyms=E;
CC         IsoId=Q16288-5; Sequence=VSP_002924, VSP_002927;
CC   -!- TISSUE SPECIFICITY: Widely expressed but mainly in nervous tissue.
CC       Isoform 2 is expressed at higher levels in adult brain than in fetal
CC       brain.
CC   -!- PTM: Ligand-mediated auto-phosphorylation.
CC   -!- DISEASE: Note=Defects in NTRK3 are associated with susceptibility to
CC       congenital heart defects (CHD). A disease characterized by congenital
CC       developmental abnormalities involving structures of the heart. CHD are
CC       the most common major birth defects and the leading cause of death from
CC       congenital malformations. {ECO:0000269|PubMed:25196463}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/NTRK3ID433.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U05012; AAA75374.1; -; mRNA.
DR   EMBL; S76475; AAB33111.1; -; mRNA.
DR   EMBL; S76476; AAB33112.1; -; mRNA.
DR   EMBL; AJ224521; CAA12029.1; -; Genomic_DNA.
DR   EMBL; AJ224522; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224523; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224524; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224525; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224526; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224527; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224528; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224529; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224530; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224531; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224532; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224533; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224534; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AJ224535; CAA12029.1; JOINED; Genomic_DNA.
DR   EMBL; AK297160; BAH12511.1; -; mRNA.
DR   EMBL; AC009711; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC011966; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC021677; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS10340.1; -. [Q16288-3]
DR   CCDS; CCDS32322.1; -. [Q16288-1]
DR   CCDS; CCDS32323.1; -. [Q16288-2]
DR   CCDS; CCDS58399.1; -. [Q16288-5]
DR   PIR; A55178; A55178.
DR   PIR; I73632; I73632.
DR   PIR; I73633; I73633.
DR   RefSeq; NP_001012338.1; NM_001012338.2. [Q16288-1]
DR   RefSeq; NP_001307063.1; NM_001320134.1.
DR   RefSeq; NP_001307064.1; NM_001320135.1.
DR   RefSeq; NP_002521.2; NM_002530.3. [Q16288-3]
DR   RefSeq; XP_016877742.1; XM_017022253.1.
DR   PDB; 1WWC; X-ray; 1.90 A; A=297-422.
DR   PDB; 3V5Q; X-ray; 2.20 A; A/B=530-832.
DR   PDB; 4YMJ; X-ray; 2.00 A; A/B=530-839.
DR   PDB; 6KZC; X-ray; 2.00 A; A=528-839.
DR   PDB; 6KZD; X-ray; 1.71 A; A=528-839.
DR   PDBsum; 1WWC; -.
DR   PDBsum; 3V5Q; -.
DR   PDBsum; 4YMJ; -.
DR   PDBsum; 6KZC; -.
DR   PDBsum; 6KZD; -.
DR   AlphaFoldDB; Q16288; -.
DR   SMR; Q16288; -.
DR   BioGRID; 110971; 64.
DR   DIP; DIP-5723N; -.
DR   IntAct; Q16288; 343.
DR   MINT; Q16288; -.
DR   STRING; 9606.ENSP00000354207; -.
DR   BindingDB; Q16288; -.
DR   ChEMBL; CHEMBL5608; -.
DR   DrugBank; DB11986; Entrectinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB14723; Larotrectinib.
DR   DrugBank; DB15822; Pralsetinib.
DR   DrugCentral; Q16288; -.
DR   GuidetoPHARMACOLOGY; 1819; -.
DR   GlyGen; Q16288; 13 sites.
DR   iPTMnet; Q16288; -.
DR   PhosphoSitePlus; Q16288; -.
DR   BioMuta; NTRK3; -.
DR   DMDM; 134035335; -.
DR   MassIVE; Q16288; -.
DR   MaxQB; Q16288; -.
DR   PaxDb; Q16288; -.
DR   PeptideAtlas; Q16288; -.
DR   PRIDE; Q16288; -.
DR   ProteomicsDB; 20249; -.
DR   ProteomicsDB; 40524; -.
DR   ProteomicsDB; 60850; -. [Q16288-1]
DR   ProteomicsDB; 60851; -. [Q16288-2]
DR   ProteomicsDB; 60852; -. [Q16288-3]
DR   ProteomicsDB; 60853; -. [Q16288-4]
DR   ABCD; Q16288; 8 sequenced antibodies.
DR   Antibodypedia; 3979; 810 antibodies from 41 providers.
DR   DNASU; 4916; -.
DR   Ensembl; ENST00000317501.8; ENSP00000318328.3; ENSG00000140538.17. [Q16288-2]
DR   Ensembl; ENST00000357724.6; ENSP00000350356.2; ENSG00000140538.17. [Q16288-4]
DR   Ensembl; ENST00000394480.6; ENSP00000377990.1; ENSG00000140538.17. [Q16288-3]
DR   Ensembl; ENST00000557856.5; ENSP00000453959.1; ENSG00000140538.17. [Q16288-5]
DR   Ensembl; ENST00000629765.3; ENSP00000485864.1; ENSG00000140538.17. [Q16288-1]
DR   Ensembl; ENST00000695462.1; ENSP00000511942.1; ENSG00000140538.17. [Q16288-1]
DR   GeneID; 4916; -.
DR   KEGG; hsa:4916; -.
DR   MANE-Select; ENST00000629765.3; ENSP00000485864.1; NM_001012338.3; NP_001012338.1.
DR   UCSC; uc059mwc.1; human. [Q16288-1]
DR   CTD; 4916; -.
DR   DisGeNET; 4916; -.
DR   GeneCards; NTRK3; -.
DR   HGNC; HGNC:8033; NTRK3.
DR   HPA; ENSG00000140538; Tissue enhanced (brain).
DR   MalaCards; NTRK3; -.
DR   MIM; 191316; gene.
DR   neXtProt; NX_Q16288; -.
DR   OpenTargets; ENSG00000140538; -.
DR   Orphanet; 2665; Congenital mesoblastic nephroma.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   Orphanet; 2030; Fibrosarcoma.
DR   PharmGKB; PA31819; -.
DR   VEuPathDB; HostDB:ENSG00000140538; -.
DR   eggNOG; KOG1026; Eukaryota.
DR   GeneTree; ENSGT00940000155645; -.
DR   HOGENOM; CLU_000288_74_1_1; -.
DR   InParanoid; Q16288; -.
DR   OMA; RXVGGHT; -.
DR   OrthoDB; 754662at2759; -.
DR   PhylomeDB; Q16288; -.
DR   TreeFam; TF106465; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; Q16288; -.
DR   Reactome; R-HSA-388844; Receptor-type tyrosine-protein phosphatases.
DR   Reactome; R-HSA-9034013; NTF3 activates NTRK3 signaling.
DR   Reactome; R-HSA-9034015; Signaling by NTRK3 (TRKC).
DR   Reactome; R-HSA-9034793; Activated NTRK3 signals through PLCG1.
DR   Reactome; R-HSA-9034864; Activated NTRK3 signals through RAS.
DR   Reactome; R-HSA-9603381; Activated NTRK3 signals through PI3K.
DR   Reactome; R-HSA-9603505; NTRK3 as a dependence receptor.
DR   SignaLink; Q16288; -.
DR   SIGNOR; Q16288; -.
DR   BioGRID-ORCS; 4916; 12 hits in 1105 CRISPR screens.
DR   ChiTaRS; NTRK3; human.
DR   EvolutionaryTrace; Q16288; -.
DR   GeneWiki; TrkC_receptor; -.
DR   GenomeRNAi; 4916; -.
DR   Pharos; Q16288; Tclin.
DR   PRO; PR:Q16288; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q16288; protein.
DR   Bgee; ENSG00000140538; Expressed in Brodmann (1909) area 10 and 173 other tissues.
DR   ExpressionAtlas; Q16288; baseline and differential.
DR   Genevisible; Q16288; HS.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0099055; C:integral component of postsynaptic membrane; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005004; F:GPI-linked ephrin receptor activity; IEA:Ensembl.
DR   GO; GO:0043121; F:neurotrophin binding; IBA:GO_Central.
DR   GO; GO:0005030; F:neurotrophin receptor activity; IDA:BHF-UCL.
DR   GO; GO:0002039; F:p53 binding; IPI:BHF-UCL.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0090630; P:activation of GTPase activity; IDA:BHF-UCL.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IDA:BHF-UCL.
DR   GO; GO:1990090; P:cellular response to nerve growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0071300; P:cellular response to retinoic acid; IEA:Ensembl.
DR   GO; GO:0090102; P:cochlea development; IEA:Ensembl.
DR   GO; GO:0007507; P:heart development; IMP:UniProtKB.
DR   GO; GO:0048712; P:negative regulation of astrocyte differentiation; IEA:Ensembl.
DR   GO; GO:0060548; P:negative regulation of cell death; IEA:Ensembl.
DR   GO; GO:0001933; P:negative regulation of protein phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0048665; P:neuron fate specification; IEA:Ensembl.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:2000251; P:positive regulation of actin cytoskeleton reorganization; IDA:BHF-UCL.
DR   GO; GO:0030335; P:positive regulation of cell migration; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:BHF-UCL.
DR   GO; GO:0010628; P:positive regulation of gene expression; IDA:BHF-UCL.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:BHF-UCL.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IBA:GO_Central.
DR   GO; GO:0033138; P:positive regulation of peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0050927; P:positive regulation of positive chemotaxis; IDA:BHF-UCL.
DR   GO; GO:0001934; P:positive regulation of protein phosphorylation; TAS:BHF-UCL.
DR   GO; GO:0099151; P:regulation of postsynaptic density assembly; IEA:Ensembl.
DR   GO; GO:1905606; P:regulation of presynapse assembly; IEA:Ensembl.
DR   GO; GO:0051896; P:regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:0048678; P:response to axon injury; IEA:Ensembl.
DR   GO; GO:0051412; P:response to corticosterone; IEA:Ensembl.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IDA:BHF-UCL.
DR   Gene3D; 2.60.40.10; -; 2.
DR   Gene3D; 3.80.10.10; -; 1.
DR   InterPro; IPR000483; Cys-rich_flank_reg_C.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR013151; Immunoglobulin.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR000372; LRRNT.
DR   InterPro; IPR020777; NTRK.
DR   InterPro; IPR020446; NTRK3.
DR   InterPro; IPR031635; NTRK_LRRCT.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00047; ig; 1.
DR   Pfam; PF13855; LRR_8; 1.
DR   Pfam; PF16920; LRRCT_2; 1.
DR   Pfam; PF01462; LRRNT; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PRINTS; PR01939; NTKRECEPTOR.
DR   PRINTS; PR01942; NTKRECEPTOR3.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00082; LRRCT; 1.
DR   SMART; SM00013; LRRNT; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS51450; LRR; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Developmental protein;
KW   Differentiation; Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Kinase; Leucine-rich repeat; Membrane; Neurogenesis;
KW   Nucleotide-binding; Phosphoprotein; Receptor; Reference proteome; Repeat;
KW   Signal; Transferase; Transmembrane; Transmembrane helix;
KW   Tyrosine-protein kinase.
FT   SIGNAL          1..31
FT   CHAIN           32..839
FT                   /note="NT-3 growth factor receptor"
FT                   /id="PRO_0000016731"
FT   TOPO_DOM        32..429
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        430..453
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        454..839
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   REPEAT          104..125
FT                   /note="LRR 1"
FT   REPEAT          128..149
FT                   /note="LRR 2"
FT   DOMAIN          160..209
FT                   /note="LRRCT"
FT   DOMAIN          210..300
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          309..382
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          538..839
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   ACT_SITE        679
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         544..552
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         572
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   SITE            516
FT                   /note="Interaction with SHC1"
FT                   /evidence="ECO:0000250"
FT   SITE            834
FT                   /note="Interaction with PLC-gamma-1"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         493
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q6VNS1"
FT   MOD_RES         516
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT   MOD_RES         705
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         709
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         710
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000250"
FT   CARBOHYD        72
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        79
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        133
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        163
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        203
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        218
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        232
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        259
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        267
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        272
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        294
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        375
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        388
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        32..38
FT                   /evidence="ECO:0000250|UniProtKB:Q91044"
FT   DISULFID        36..45
FT                   /evidence="ECO:0000250|UniProtKB:Q91044"
FT   DISULFID        164..189
FT                   /evidence="ECO:0000250|UniProtKB:Q91044"
FT   DISULFID        166..207
FT                   /evidence="ECO:0000250|UniProtKB:Q91044"
FT   DISULFID        231..284
FT                   /evidence="ECO:0000250|UniProtKB:Q91044"
FT   DISULFID        320..362
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114,
FT                   ECO:0000269|PubMed:10388563, ECO:0007744|PDB:1WWC"
FT   VAR_SEQ         402..410
FT                   /note="ESTDNFILF -> V (in isoform 4 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_002924"
FT   VAR_SEQ         529..612
FT                   /note="YVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLA
FT                   ARKDFQREAELLTNLQHEHIVKFYGVCGDGDP -> WVFSNIDNHGILNLKDNRDHLVP
FT                   STHYIYEEPEVQSGEVSYPRSHGFREIMLNPISLPGHSKPLNHGIYVEDVNVYFSKGRH
FT                   GF (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7823156"
FT                   /id="VSP_002925"
FT   VAR_SEQ         613..839
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7823156"
FT                   /id="VSP_002926"
FT   VAR_SEQ         712..725
FT                   /note="Missing (in isoform 3 and isoform 5)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:7806211, ECO:0000303|PubMed:7823156"
FT                   /id="VSP_002927"
FT   VARIANT         21
FT                   /note="V -> F (in dbSNP:rs200822610)"
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT                   /id="VAR_074601"
FT   VARIANT         71
FT                   /note="I -> V (found in patients with CHD; unknown
FT                   pathological significance; dbSNP:rs200923715)"
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT                   /id="VAR_074602"
FT   VARIANT         93
FT                   /note="T -> M (probable disease-associated variant found in
FT                   patients with CHD; associated with CHD susceptibility;
FT                   significantly reduced autophosphorylation; decreased NTRK3
FT                   signaling associated with decreased apoptosis in absence of
FT                   NTF3; dbSNP:rs147992979)"
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT                   /id="VAR_074603"
FT   VARIANT         149
FT                   /note="T -> R (in a gastric adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs368222977)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041471"
FT   VARIANT         163
FT                   /note="N -> I (found in patients with CHD; unknown
FT                   pathological significance; no change in
FT                   autophosphorylation; no effect on NTRK3 signaling;
FT                   dbSNP:rs547862658)"
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT                   /id="VAR_074604"
FT   VARIANT         306
FT                   /note="R -> C (in dbSNP:rs56386352)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041472"
FT   VARIANT         307
FT                   /note="V -> L (in a lung adenocarcinoma sample; somatic
FT                   mutation; dbSNP:rs1388363572)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041473"
FT   VARIANT         336
FT                   /note="L -> Q (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041474"
FT   VARIANT         533
FT                   /note="I -> F (probable disease-associated variant found in
FT                   patients with CHD; associated with CHD susceptibility; no
FT                   change in autophosphorylation; changed NTRK3 signaling with
FT                   decreased apoptosis in absence of NTF3; dbSNP:rs869112057)"
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT                   /id="VAR_074605"
FT   VARIANT         664
FT                   /note="A -> S (in a lung carcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:18293376"
FT                   /id="VAR_046521"
FT   VARIANT         677
FT                   /note="H -> Y (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:18293376"
FT                   /id="VAR_041475"
FT   VARIANT         678
FT                   /note="R -> Q (in dbSNP:rs55890138)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041476"
FT   VARIANT         735
FT                   /note="R -> F (in a lung large cell carcinoma sample;
FT                   somatic mutation; requires 2 nucleotide substitutions)"
FT                   /id="VAR_046770"
FT   VARIANT         736
FT                   /note="W -> C (in a lung carcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:18293376"
FT                   /id="VAR_046522"
FT   VARIANT         745
FT                   /note="R -> P (in a lung carcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:18293376"
FT                   /id="VAR_046523"
FT   VARIANT         766
FT                   /note="Y -> F (in a lung carcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:18293376"
FT                   /id="VAR_046524"
FT   VARIANT         768
FT                   /note="K -> R (in dbSNP:rs55770052)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046771"
FT   VARIANT         781
FT                   /note="E -> K (in dbSNP:rs56393451)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_046772"
FT   VARIANT         817
FT                   /note="I -> M (probable disease-associated variant found in
FT                   patients with CHD; associated with CHD susceptibility; no
FT                   change in autophosphorylation; changed NTRK3 signaling with
FT                   decreased apoptosis in absence of NTF3; dbSNP:rs869209165)"
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT                   /id="VAR_074606"
FT   MUTAGEN         572
FT                   /note="K->N: Loss of autophosphorylation and loss of NTRK3
FT                   signaling."
FT                   /evidence="ECO:0000269|PubMed:25196463"
FT   CONFLICT        65
FT                   /note="S -> G (in Ref. 4; BAH12511)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        70
FT                   /note="S -> N (in Ref. 2; AAB33111/AAB33112)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        635
FT                   /note="D -> N (in Ref. 1; AAA75374)"
FT                   /evidence="ECO:0000305"
FT   STRAND          318..326
FT                   /evidence="ECO:0007829|PDB:1WWC"
FT   STRAND          332..337
FT                   /evidence="ECO:0007829|PDB:1WWC"
FT   STRAND          345..354
FT                   /evidence="ECO:0007829|PDB:1WWC"
FT   STRAND          356..367
FT                   /evidence="ECO:0007829|PDB:1WWC"
FT   HELIX           370..372
FT                   /evidence="ECO:0007829|PDB:1WWC"
FT   STRAND          374..382
FT                   /evidence="ECO:0007829|PDB:1WWC"
FT   STRAND          385..393
FT                   /evidence="ECO:0007829|PDB:1WWC"
FT   HELIX           535..537
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          538..547
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          550..559
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          567..576
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           579..594
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          603..606
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          609..618
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           625..631
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           653..672
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           682..684
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          685..687
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           689..691
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          693..695
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   STRAND          700..704
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           706..708
FT                   /evidence="ECO:0007829|PDB:4YMJ"
FT   HELIX           734..736
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           739..744
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           749..764
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   TURN            765..767
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   TURN            770..773
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           776..784
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           797..806
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           811..813
FT                   /evidence="ECO:0007829|PDB:6KZD"
FT   HELIX           817..827
FT                   /evidence="ECO:0007829|PDB:6KZD"
SQ   SEQUENCE   839 AA;  94428 MW;  7FE8846830083C08 CRC64;
     MDVSLCPAKC SFWRIFLLGS VWLDYVGSVL ACPANCVCSK TEINCRRPDD GNLFPLLEGQ
     DSGNSNGNAS INITDISRNI TSIHIENWRS LHTLNAVDME LYTGLQKLTI KNSGLRSIQP
     RAFAKNPHLR YINLSSNRLT TLSWQLFQTL SLRELQLEQN FFNCSCDIRW MQLWQEQGEA
     KLNSQNLYCI NADGSQLPLF RMNISQCDLP EISVSHVNLT VREGDNAVIT CNGSGSPLPD
     VDWIVTGLQS INTHQTNLNW TNVHAINLTL VNVTSEDNGF TLTCIAENVV GMSNASVALT
     VYYPPRVVSL EEPELRLEHC IEFVVRGNPP PTLHWLHNGQ PLRESKIIHV EYYQEGEISE
     GCLLFNKPTH YNNGNYTLIA KNPLGTANQT INGHFLKEPF PESTDNFILF DEVSPTPPIT
     VTHKPEEDTF GVSIAVGLAA FACVLLVVLF VMINKYGRRS KFGMKGPVAV ISGEEDSASP
     LHHINHGITT PSSLDAGPDT VVIGMTRIPV IENPQYFRQG HNCHKPDTYV QHIKRRDIVL
     KRELGEGAFG KVFLAECYNL SPTKDKMLVA VKALKDPTLA ARKDFQREAE LLTNLQHEHI
     VKFYGVCGDG DPLIMVFEYM KHGDLNKFLR AHGPDAMILV DGQPRQAKGE LGLSQMLHIA
     SQIASGMVYL ASQHFVHRDL ATRNCLVGAN LLVKIGDFGM SRDVYSTDYY RLFNPSGNDF
     CIWCEVGGHT MLPIRWMPPE SIMYRKFTTE SDVWSFGVIL WEIFTYGKQP WFQLSNTEVI
     ECITQGRVLE RPRVCPKEVY DVMLGCWQRE PQQRLNIKEI YKILHALGKA TPIYLDILG
//
